PL3727349T3 - Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego - Google Patents

Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego

Info

Publication number
PL3727349T3
PL3727349T3 PL18822053.7T PL18822053T PL3727349T3 PL 3727349 T3 PL3727349 T3 PL 3727349T3 PL 18822053 T PL18822053 T PL 18822053T PL 3727349 T3 PL3727349 T3 PL 3727349T3
Authority
PL
Poland
Prior art keywords
nanoparticles
treatment
neuronal disorders
neuronal
disorders
Prior art date
Application number
PL18822053.7T
Other languages
English (en)
Inventor
Marie-Edith MEYRE
Laurent Levy
Agnès Pottier
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of PL3727349T3 publication Critical patent/PL3727349T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5115Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18822053.7T 2017-12-19 2018-12-18 Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego PL3727349T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306826 2017-12-19
PCT/EP2018/085593 WO2019121748A1 (en) 2017-12-19 2018-12-18 Nanoparticles for use for treating a neuronal disorder

Publications (1)

Publication Number Publication Date
PL3727349T3 true PL3727349T3 (pl) 2025-02-10

Family

ID=60954823

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18822053.7T PL3727349T3 (pl) 2017-12-19 2018-12-18 Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego

Country Status (16)

Country Link
US (1) US11497717B2 (pl)
EP (1) EP3727349B1 (pl)
JP (3) JP7424640B2 (pl)
KR (1) KR102729931B1 (pl)
CN (1) CN111886004A (pl)
AU (1) AU2018391789B2 (pl)
BR (1) BR112020012214A2 (pl)
ES (1) ES2991899T3 (pl)
HU (1) HUE068741T2 (pl)
IL (1) IL275408B2 (pl)
MX (1) MX2020006360A (pl)
PL (1) PL3727349T3 (pl)
PT (1) PT3727349T (pl)
UA (1) UA128390C2 (pl)
WO (1) WO2019121748A1 (pl)
ZA (1) ZA202004344B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2998117T3 (en) 2017-12-19 2025-02-19 Nanobiotix Nanoparticles for use in enhancing brain performances or in treating stress
CA3084780A1 (en) * 2020-06-24 2021-12-24 Rodney HERRING Use of low iron oxide iron-doped titanium dioxide nanoparticles in the treatment of tumors and other diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835A (en) 1844-11-26 Improvement in cotton-presses
CA2664919A1 (en) 2006-08-08 2008-02-21 Board Of Regents Of The University Of Texas Multistage delivery of active agents
WO2009052295A2 (en) 2007-10-16 2009-04-23 Edward Via Virginia College Of Osteopathic Medicine Cerium oxide nanoparticles for treatment and prevention of alzheimer's disease, parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction
WO2010054017A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
KR101931381B1 (ko) 2009-07-08 2018-12-20 클레네 나노메디슨, 인크. 의학적 치료를 위한 신규한 금계 나노결정 및 이를 위한 전기화학 제조 방법
EP2540169B1 (en) 2010-02-26 2016-07-06 Universidad de Navarra Nanoparticles for the encapsulation of compounds, preparation thereof and use of same
PL2670394T3 (pl) 2011-01-31 2019-03-29 Nanobiotix Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania
MX2014015251A (es) 2012-06-13 2015-04-13 Cerion Entpr Llc Nanocerios para el tratamiento del estres oxidativo.
EP2974717A3 (en) 2014-07-16 2016-04-13 GNT Biotech & Medicals Corporation Use of nano metal in promoting neurite outgrowth and treatment and/or prevention of neurological disorders
WO2016083336A1 (en) * 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
WO2017060916A1 (en) 2015-10-09 2017-04-13 NOUSHAD Javed Md Metallic nanoparticle alone and/or in combination as novel agent for the treatment of uncontrolled electric conductance related disorders and/or seizure, epilepsy & convulsions.
US20170290916A1 (en) 2016-04-07 2017-10-12 The Florida International University Board Of Trustees Materials and Methods for the Delivery of a Nanocarrier to the Brain
JP7766899B2 (ja) * 2016-12-21 2025-11-11 ナノビオティックス 神経障害を処置するのに使用するためのナノ粒子
EA201991521A1 (ru) 2016-12-21 2019-12-30 Нанобиотикс Наночастицы для применения для улучшения деятельности мозга или для лечения стресса
WO2018115023A1 (en) 2016-12-21 2018-06-28 Nanobiotix Coated nanoparticles for use for modulating electrical polarization of neurons
ES2998117T3 (en) 2017-12-19 2025-02-19 Nanobiotix Nanoparticles for use in enhancing brain performances or in treating stress
US20200015750A1 (en) 2018-07-11 2020-01-16 Patriot Worldwide, Inc. Needle assembly with temperature measurement device

Also Published As

Publication number Publication date
EP3727349B1 (en) 2024-08-07
ES2991899T3 (es) 2024-12-05
JP2025163111A (ja) 2025-10-28
KR102729931B1 (ko) 2024-11-13
US20210015756A1 (en) 2021-01-21
IL275408B2 (en) 2024-06-01
HUE068741T2 (hu) 2025-01-28
JP7424640B2 (ja) 2024-01-30
JP2024038335A (ja) 2024-03-19
UA128390C2 (uk) 2024-07-03
KR20200110321A (ko) 2020-09-23
ZA202004344B (en) 2023-10-25
IL275408B1 (en) 2024-02-01
IL275408A (en) 2020-07-30
JP7725096B2 (ja) 2025-08-19
NZ766044A (en) 2025-09-26
EP3727349A1 (en) 2020-10-28
US11497717B2 (en) 2022-11-15
BR112020012214A2 (pt) 2020-11-24
RU2020123702A (ru) 2022-01-21
CA3085528A1 (en) 2019-06-27
CN111886004A (zh) 2020-11-03
WO2019121748A1 (en) 2019-06-27
AU2018391789A1 (en) 2020-07-23
MX2020006360A (es) 2020-08-17
PT3727349T (pt) 2024-10-31
RU2020123702A3 (pl) 2022-01-21
AU2018391789B2 (en) 2024-05-23
JP2021506873A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
CY2023010I1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
IL279752A (en) Polycyclic compounds and use thereof in the treatment of immune disorders
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
IL263484A (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
HUE050095T2 (hu) Anyagcsere-rendellenességek kezelése lófélékben
HUE059559T2 (hu) 5HT agonisták az epilepsziás rendellenességek kezelésére
PT3119397T (pt) Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
EP3539600C0 (en) DEVICE SUITABLE FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
HRP20180260T1 (hr) Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja
HRP20180337T1 (hr) Kalcitonin mimetika za liječenje bolesti i poremećaja
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
PL3432872T3 (pl) Eflornityna do zastosowania w leczeniu nawracającego/opornego na leczenie temozolomidem gwiaździaka anaplastycznego
IL270900A (en) Treatment of cutaneous disorders
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
IL260987A (en) Treatment and diagnosis of inflammatory disorders
EP3373888A4 (en) METHOD FOR THE TREATMENT OF SKIN DISEASES USING PLASMONIC NANOPARTICLES
IL263080B (en) Treatment of neurological disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
PL3727349T3 (pl) Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego